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Elena I. Fedorosc,d and Andrey V. PanchenkodA method of platinum quantification in whole blood samples after microwave digestion using sector field inductively coupled
plasmamass spectrometry has been developed. The following analytical figures ofmerit have been established: limit of detection
1.1 μg/L for blood samples, dynamic range 3.6–200 μg/L, intra-day precision (relative standard deviation, n = 9) did not exceed 5%.
Spiked samples were analyzed for method validation. The method was used for pharmacokinetics studies of a novel anti-cancer
drug BP-С1, a complex of cis-configured platinum and benzene-poly-carboxylic acids. Main pharmacokinetic parameters (area
under curve, maximum concentration, clearance, half-life times for α- and β-phase) were estimated for two dosage forms
of BP-C1 0.05 and 0.125 mass %. Pharmacokinetic curves were assessed for single and course administration. Studies were
performed using rabbits (n = 6) as a model. BP-C1 was injected intramuscularly. The study established dose proportionality
of the tested dosage forms and suggested clinical dosing schedule: 5 days of injections followed by 2 days’ break. Platinum tissue
distribution was studied in tissue samples collected 20 days after the last injection. Predominant platinum accumulation was
observed in kidneys, liver, and muscles near injection site. ‘Slow’ phase of platinum excretion kinetics may be related to the mus-
cles at the injection site. © 2015 The Authors. Drug Testing and Analysis published by John Wiley & Sons Ltd.
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Platinum (Pt) complexes, cytotoxic action of which is related to DNA
binding[1] and replication suppression,[2] belong to the class of che-
motherapeutic drugs. The first clinically approved[3] and the most
studied of the group is cis-dichlorodiammineplatinum (II), cisplatin.
High toxicity and severe side effects of cisplatin (nephro- and oto-
toxicity, peripheral nervous system disorders)[4–6] inspired research
into new platinum-containing cytostatics. The second approved
and less toxic compared to cisplatin was cis-diammine(1,
1-cyclobutanedicarboxylato)platinum (II), carboplatin.[7] In total,
since the late 1960s, a considerable number of platinum and
other d-elements, e.g. palladium, ruthenium, osmium, iridium, etc.,
complexes were tested for antitumor activity.[8–10] Although
numerous studies related to new platinum compounds synthesis
and their efficacy evaluation have been undertaken, insufficient
selectivity for malignant cells, severe side effects and drug resistance
developed by some tumours, are still a characteristic feature of
these drugs.[11,12]
Platinum-containing chemotherapy agents with physiologically
active ligands seem to be a perspective direction in anti-cancer drug
design. In any platinum-containing drug a ligand should, first of all
provide a stable therapeutic concentration of platinum in the system
bloodstream. Consequently, pharmacokinetics studies are one of the
key aspects of drug design for this group of compounds. The subject
of the present study was pharmacokinetics of the novel anti-cancerDrug Test. Analysis 2015, 7, 737–744 © 2015agent BP-C1 (international patent WO2013/143549 A1), developed
for therapy of metastatic breast and pancreas cancers. BP-C1 is a
complex of cis-configured platinum (II) with benzene-poly-carboxylic
acids. The novel ligand is assumed to possess highly functionalized
poly-phenolic backbone, whichmay contribute to additional tumour
suppressing effect via immune modulation and inducing cytokine
production (e.g. TNF-α, IFN-γ, IL-1β, IL6, IL25).[13] BP-C1 was shown
to activate pro-apoptotic gene expression and inhibit oncogenes.[14]
The agent is undergoing controlled Phase II clinical trials.[15]The Authors. Drug Testing and Analysis published by John Wiley & Sons Ltd.
7
D. V. Navolotskii et al.
Drug Testing
and Analysis
7
38Chemical analysis plays an important role in the acquisition of
pharmacokinetic data.[16,17] Rather strict requirements for analytical
methods have stimulated a newmethod development for the anal-
ysis of drug dosage forms and rawmaterials as well as for the detec-
tion of pharmaceutical agents and their metabolites in biological
media.[18] Nowadays, one of the techniques available for platinum
quantification in biological fluids and tissues is double-focusing
sector-field inductively coupled plasma mass spectrometry
(ICP-MS). Providing high selectivity and low limit of detection
(LOD),[19] it may be called a technique of choice for elemental
pharmaceutical analysis. The aim of the present study was method
development for platinum determination in the blood and evalua-
tion of pharmacokinetics of BP-C1.Materials and methods
Instrumentation
For platinum quantification, a double-focusing sector-field induc-
tively coupled plasma mass spectrometer Thermo Scientific™ Ele-
ment 2 (Thermo Fisher Scientific, Bremen, Germany) was used.
Meinhard-type concentric nebuliser and +4°C Peltier cooled glass
spray chamber were employed for sample introduction. Microwave
digestion system Start D (Milestone, Sorisole, Italy) with high-
pressure vials of polytetrafluoroethylene was used for sample pre-
treatment. Milli-Q® Advantage A10 (Millipore, Molsheim, France)
system was a source of ultra pure water.
Standards and chemicals
Calibration and spiking standard was CertiPUR® Platinum ICP stan-
dard 1000 mg/L Pt (Merck, Darmstadt, Germany). Rhodium CGRHN-
1 1001 ± 5 μg/mL (Inorganic Ventures, Christiansberg, VA, USA) was
employed as an internal standard. For interference studies Multi-
Element Calibration Standards of Atomic Spectroscopy Standard
series (PerkinElmer, Shelton, CT, USA) were analyzed. For blood
and tissue sample digestion and calibration solution stabilization
Suprapur® nitric acid (65%, Merck, Darmstadt, Germany) was used.
BP-C1 was provided by Meabco A/S (Copenhagen, Denmark).
Throughout this study two dosage forms of BP-C1 were investi-
gated: 0.125% injection solution in physiologic saline containing
110.6 μg/mL platinum (confirmed by sector field ICP-MS) and
0.05% injection solution in physiologic saline containing 51.4
μg/mL platinum (confirmed by sector field ICP-MS).
Animal keeping and study groups
The study was conducted in 6 adult male chinchilla rabbits (body
weight 2900±192 g). Animals were kept in individual cages and pro-
vided with water and standard rabbit chow ad libitum. BP-C1 (both
0.05 and 0.125% forms) was injected to rabbits intramuscularly in
the volume of 1 mL per 3 kg of body weight in accordance with theTable 1. Groups, animals, injection and blood sampling schedule
Group Animals Sampling after the
first single injection
Inje
0.125% 1, 2, 3 (series 1) 0.25, 0.5, 1, 2, 4, 8, 24, 48 and
144 h after the first injection
Days 0, 1,
17, 18, 214, 5, 6 (series 2)
0.05% 4, 5, 6 (series 1)
1, 2, 3 (series 2)
wileyonlinelibrary.com/journal/dta © 2015 The Authors. D
Analysis published bystudy design. At the end of the study animals were euthanized with
intravenous propofol injection and organs were excised for platinum
tissue distribution studies. All animal experiments were conducted in
accordance with ethical regulation and were approved by the ethics
committee of the N.N. Petrov Research Institute of Oncology.Pre-clinical study design and sample collection
The pharmacokinetics study was performed in three stages within
two series of experiments: kinetics studies of the single injection
(the first administration), kinetics studies of the course treatment (mul-
tiple injections, stationary platinum level) and excretion kinetics (the
last injection). In the first set of experiments rabbits 1, 2, and 3 received
1 mL of the 0.125% BP-C1 dosage form (group 0.125%). Animals 4, 5
and 6 were given 1 mL of the 0.05% BP-C1 dosage form (group
0.05%). In the second series, animals were crossed-over, so that those
previously given the higher dosage were switched to the 0.05% dos-
age and vice versa. The break between the series constituted 19 days.
Design of each series envisaged collection of blood samples each
working day following the first test-drug injection. The last blood
sampling was performed 144 h after the initial injection. Afterwards,
the same animals were used for studying the kinetics of multiple
injections, which were given 22 injections (5 injections per week for
4 weeks). In the last week, animals were injected only twice. To study
the single injection kinetics and excretion, samples were collected
before BP-C1 injection as well as 0.25, 0.5, 1, 2, 4, 8, 24, 48, and 144
h after the injection. For the multiple injection studies (stationary
level) blood was sampled directly before the next injection (once
per day). After the last injection (excretion kinetics) samples were
collected similar to the single dose studies and also on days 8, 10,
and 15. For details on injection and sampling design, see Table 1.
Whole blood samples were used previously for platinum contain-
ing drugs pharmacokinetic studies, for example in the case of
oxaliplatin, [(1R,2R)-cyclohexane-1,2-diamine] (ethanedioato-O,O’)
platinum(II).[20,21] In the current study, whole blood samples were
taken from marginal ear vein. Lithium-heparin (1300–1500 U/tube)
6 mL Vacutest® vacuum systems (Vacutest KIMA, Arzergrande, Italy)
were used for blood sampling. Samples were frozen at –20°C and
sent to analytical facility for analysis. Organs were sampled during
autopsy, 20 days after the last BP-C1 injection, using surgical instru-
ments, tightly packed in sterile polyethylene bags, frozen at 20°C
and transported for analysis. The following tissues were examined:
brain, heart, left kidney, right kidney, liver, lungs, pancreas, urinary
bladder, spleen, muscular tissue (near injection site), muscular tissue
(intact), skin (near injection site) and skin (intact). Bones were not
analyzed since this tissue was demonstrated to accumulate only
minor levels of platinum.[22]Sample preparation
Samples were thawed at +4°C. After that, 0.5 mL of whole blood or
100 mg of biological tissue were digested in microwave systemctions and sampling for
course treatment
Sampling for final
excretion kinetics
2, 4, 7, 8, 9, 10, 11, 14, 15, 16,
, 22, 23, 24, 25, 28, 29, 30
0.25, 0.5, 1, 2, 4, 8, 24, 48, 144, 192, 240
and 360 h after the last injection
rug Testing and
John Wiley & Sons Ltd.
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tissue respectively, and 5mLMilli-Q® water. Mineralization was per-
formed for 30 min (maximum autoclave temperature 185°C, power
1000 W). Solutions, acquired after digestion, were diluted to the fi-
nal volume of 25 mL in PFA volumetric flasks. At this stage, internal
standard (rhodium) was added to the final concentration of 1μg/L.
Samples were handled with all necessary precautions to avoid
possible contamination.
Statistics
Method validation was performed in accordance with the United
States Food and Drug Administration Guidelines on bioanalytical
methods.[23] Spiked samples were analyzed to estimate LODs, pre-
cision, accuracy, repeatability, linearity, and dynamic range. Blood
and tissue samples were spiked with standard solution of platinum
prior to digestion. Pharmacokinetics data was evaluated using both
model-independent calculation and three-compartment model.[24]
Three-compartment modelling was chosen since pilot study with
two animals demonstrated prolonged ‘slow’ platinum excretion
kinetics, which cannot be adequately described with two-exponential
representation. Standard Microsoft Excel® 2007 software (Microsoft,
Redmond, WA, USA) was used for statistical calculations.7
39Results
Blood and tissue platinum assessment method development
The most abundant (33.832%) platinum isotope 195Pt was used for
quantification with peak area registration. This isotope is not ham-
pered with spectral interferences except for overlapping with
179Hf16O, 183W12C, 182W13C and 180Hf15N. However, according to
the published data,[25,26] these interferences are insignificant for
biological samples. Our own interference modelling supported this
notion. However, for medium resolution mode (R=4000) better
intra-day precision was observed. The following optimized parame-
ters were employed: medium resolution (R=4000), high frequency
generator power 1170 W, plasma argon flow 16 L/min, auxiliary
argon flow 0.72 L/min, nebulizer argon flow 0.93 L/min, spray
chamber temperature +4°C.
Analytical procedure
The whole blood or biological tissues, treated as described in the
‘Sample preparation’ section, were analyzed using mass spectrom-
eter Thermo Scientific Element 2. Analysis result was calculated as
mean of 9 replicate measurements of the corresponding mass to
charge ratio unless relative standard deviation (RSD) exceeded
5%. Otherwise, measurements were repeated after elimination of
the cause of unsatisfactory precision. External calibration was made
using aqueous standards of 0.6, 0.8, 1.0, 2.0, 4.0 and 5.0 μg/L plati-
num and 1 μg/L of internal standard (rhodium). Calibrationwas per-
formed directly before analyzing real samples and its stability was
controlled after each 10 samples. Control and correction of mass
analyzer calibration, nebulizer performance and inductively
coupled plasma parameters was performed daily prior to analysis.
Method validation
Samples containing standard additions of platinum were digested
in accordance with the sample preparation procedure. Concentra-
tion of standard additions was 0, 50, 100, 200 μg/L Pt (adjustedDrug Test. Analysis 2015, 7, 737–744 © 2015 The Authors
Analysis published bfor the final sample dilution to 1/50 by volume). Samples were pre-
pared as follows: in digestion autoclaves 0, 250, 500, 750 and 1000
μL of 100 μg/L platinum standard, diluted from CertiPUR® Platinum
ICP standard, were spiked into 0.5mL ofwhole blood and 5.00, 4.75,
4.50, 4.25, and 4.00 mL of Milli-Q® water was added. Microwave
digested samples were diluted in PFA volumetric flasks of 25 mL
with Milli-Q® water. For validation studies each spiked sample was
analyzed five times (n = 5).
LODs, linearity, and dynamic range
Detection limit corresponding to signal-to-noise ratio of 3.3 was
found to be 1.10 μg/L. Linearity was evaluated using Fisher’s F-test.
Dispersions between calculated and experimental values were
compared to dispersion between average and individual values
(F=1.2< Fcrit. = 2.1). Statistical significance of free parameter of
linear regression (y= a+ bx) was also estimated. According to
Student’s t-test, free parameter a was found to be statistically
equal to zero (tcalc. = 0.62< t95%, n2 = 23 = 2.07). Lower limit of
quantification (LLOQ) corresponding to signal-to-noise ratio of
10 was 3.6 μg/L. Upper limit was 200 μg/L. Correlation coeffi-
cient for linear calibration was 1.0000.
Accuracy and repeatability
Method accuracy was evaluated using confidence half-interval
(P=0.95; n=5) for spiked/recovered ratios. Acquired value (4.5%)
did not exceed established value for bioanalytical quantification
methods (5%).[23]
Repeatability was estimated as relative standard deviation for 5
replicates within the dynamic range. It was found to be 4.4% which
is statistically insignificant (β=0.05) compared to the established
value for method uncertainty (5%).[23]
Pharmacokinetics studies of BP-C1
Pharmacokinetics curve for single and multiple BP-C1 injections
Pharmacokinetic and dose proportionality studies of BP-C1 in dos-
age forms of 0.05% and 0.125% were started from evaluation of ki-
netics of the single intramuscular injection. Experimental curves are
shown in Figure 1. In Figure 2 stationary concentration studies for
the course treatment are presented.
Platinum tissue distribution after BP-C1 course treatment
(multiple injections)
Mean platinum concentrations in animal tissues and standard
deviations (SD) are presented in Table 2. To examine platinum
distribution, relative concentrations of platinum in respective tissue
to platinum level for blood collected prior to euthanasia were
calculated. Ratios for higher and lower dosage were also studied
to eradicate primary accumulation organs.Discussion
Developed method
Comparing the dynamic range (3.6–200 μg/L) of the developed
method to the results acquired for digested blood samples
(Figures 1 and 2) and biological tissues (Table 2) as well as evaluation
of the method accuracy (4.5%) confirmed compliance of the method
with bioanalytical method requirements.[23] Recently, Kristiansen
et al.[27] reported BP-C1 efficacy in veterinary treatment of canine
mammary tumours; they also presented pharmacokinetics data in. Drug Testing and
y John Wiley & Sons Ltd.
wileyonlinelibrary.com/journal/dta
Figure 2. Animal averaged (n = 6) pharmacokinetics curves for the 30 days course treatment (22 injections, 5 days with 2 days’ break, 50 days of observation
total), including after course platinum excretion, corrected curves account previously administrated ‘background’ platinum in cross series and calculated using
exponential modelling for background.
Figure 1. Animal averaged (n = 6) pharmacokinetics curves after the single BP-C1 administration, corrected curves account previously administrated
‘background’ platinum in cross series and calculated using exponential modelling for background.
Table 2. Tissue mean platinum concentration (n = 3) 20 days after the end of the cross-over course for each group of animals. Blood platinum concen-
tration before euthanasia (Mean ± SD) was 6.60 ± 1.43 and 3.17 ± 0.07 μg/L for dosages of 0.125% and 0.05% (ratio 2.08), respectively
Tissue Dose 0.125%, μg/kg Dose 0.05%, μg/kg 0.125%/
0.05% ratio
Mean SD Tissue / blood Mean SD Tissue / blood
Left kidney 1101 75.9 167 579 79.2 183 1.90
Right kidney 1099 125 167 576 62.9 182 1.91
Liver 816 24.9 124 574 63.6 181 1.42
Lung 29.7 2.19 4.49 18.7 1.86 5.89 1.59
Pancreas 17.7 1.86 2.68 13.7 2.19 4.32 1.29
Prostate 41.0 5.29 6.21 24.3 4.67 7.68 1.68
Urinary bladder 57.7 5.24 8.74 32.0 6.11 10.1 1.80
Spleen 757 197 115 335 109 106 2.26
Brain 8.67 0.88 1.31 4.00 1.00 1.26 2.17
Heart 39.0 4.58 5.91 23.7 1.67 7.47 1.65
Muscles, injection site 1198 701 181 3455 1155 1091 0.35
Muscles, intact 12.0 3.51 1.82 14.3 3.53 4.53 0.84
Skin, injection site 220 135 33.4 401 208 127 0.55
Skin, intact 44.3 3.48 6.72 32.3 2.03 10.2 1.37
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Table 3. Pharmacokinetics parameters (Mean ± SD) calculated for the
first single injection, averaged for all animals (n = 6) after both stages
of the study. Three compartment modelling and model-independent
calculation were used
Parameter Mean ± SD
Group 0.125% Group 0.05%
Сmax*, μg/L 35.2 15.3
Сmax, μg/L 31.1 ± 1.2 16.0 ± 0.2
AUC0-144*, μg
.h/L 1023 462
AUC0-1, (μg
.h)/L 1682 ± 145 1387 ± 83
Cl, L/(h.kg) 0.022 ± 0.002 0.012 ± 0.0007
T½α, h 0.810 ± 0.016 0.797 ± 0.016
T½β1, h 63.0 ± 1.4 64.2 ± 0.5
T½β2, h 142 ± 30 231 ± 49
* – direct model-independent calculation.
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41dogs for single subcutaneous injection of BP-C1 within 48 h of obser-
vation and for 16 days course treatment consisting of 8 subcutane-
ous injections. However, pharmacokinetics data from this study and
our own are difficult to compare since different biological species
(dogs vs. rabbits) and different dosages (3.7 μg/kg Pt vs. 38.1 and
17.7μg/kg Pt for the current study) were employed. Nevertheless,
Kristiansen et al.[27] also showed quite slow excretion of platinum.
To the best of our knowledge (Web of Science Core Collection and
Scopus databases), there is no published pharmacokinetics data on
platinum-benzene-poly-carboxylic acid complexes after intramuscu-
lar injection in rabbits.
In general, major pharmacokinetics data of platinum-containing
chemotherapy drugs pertain to both pre-clinical[28,29] and clinical
trials.[30,31] The most frequently used techniques are ICP-MS[31–34]
and atomic absorption spectrometry (AAS) with flameless
atomization.[35,36] Chromatographic methods and molecular mass
spectrometry are also applied quite frequently.[2,37–39] Advantages
of AAS are good instrumental availability and established method-
ical approaches to biological sample analysis.[40] Nevertheless,
relatively high limit of detection in the range of < 0.3~30μg/L
(depending on sample analyzed and sample pretreatment
procedure[41–45]), considerably confines application of AAS, espe-
cially for analysis of samples from ‘slow’ excretion phases of studies.
ICP-MS makes possible lowering detection limit to the level of
0.0005 μg/L for blood plasma ultrafiltrate.[31] Moreover, use of dou-
ble focusing sector field ICP-MS enables both detection limit and
selectivity improvement leading to reliable assessment of platinum
concentration especially at ‘slow’ excretion phases.[46,47] In the
current study, in order to achieve higher sample output rather high
sample dilution (1/50 per volume) was used. That resulted in ele-
vated lower limit of quantification for sector field ICP-MS. However,
it should be noted that dynamic range corresponded to measured
platinum concentration in the analyzed samples.
BP-C1 pharmacokinetics
For the single injection kinetics (Figure 1) experimental curve could
be rather easily divided into tissue distribution stage (α-phase) and
platinum excretion stage (β-phase). The β-phase could be further
subdivided into two semi-phases β1 and β2. Distribution phase took
less than 2 h; after that, distribution to elimination transition stage
(ca 2–24 h post injection) and per se β-phase followed.
Based on acquired results major pharmacokinetics parameters
were estimated: area under curve (AUC), platinum maximum
concentration (Cmax), clearance, and half-life times corresponding
to α, β1 and β2 phases (Table 3). Maximum concentration was
achieved at ~ 0.5 h for the 0.125% concentration and only at
~ 0.25 h for the 0.05%. Notably, experimental pharmacokinetics
curves (Figure 1) for BP-C1 were in concordance with previously
published results for other platinum-containing drugs, having
rather fast metal redistribution into organs and tissues from the
bloodstream within several hours after administration as well as
prolonged platinum excretion.[27,35]
Direct model-independent calculation of maximum concentra-
tion (Сmax
*) and area under curve (AUC0-144
* ) showed dose propor-
tionality of the two studied forms of BP-C1, since both Cmax and
AUC increased proportionally for the higher dose. Noteworthy, for
three-compartment modelling average area under curve (AUC0-1)
for the lower dosage of 0.05%was found somewhat overestimated.
That may be related to residual excretion of platinum remained
after the first set of BP-C1 injections as it was typical for ani-
mals, which received the 0.125% dosage form within the firstDrug Test. Analysis 2015, 7, 737–744 © 2015 The Authors
Analysis published bexperimental series. Presence of ‘residual platinum’ from the previ-
ous BP-C1 administration is also supported with unexpectedly high
value of T½β2 for the 0.05% dosage form.
Under the course treatment with previously described design
stationary blood platinum concentration was established 10 days
after the first injection for the 0.05% dosage form and not earlier
than in 15 days in case of the 0.125% form (Figure 2). Pharmacoki-
netics studies of multiple injections support the following dosing
schedule: 5 days intramuscular injections of BP-C1 (from Monday
to Friday) with two days break for a weekend. Such dosing schedule
could be called ‘patient-oriented’ as it makes hospitalization non-
mandatory and allows ambulatory treatment or even treatment at
home. This is very important from the patient psychological
state standpoint and also lowers the costs of the treatment.
Finally, BP-C1 post-course kinetics revealed a tendency for de-
layed excretion of lower dosages of the agent and prolonged
elimination of the metal from the bloodstream. The ‘slow’ excre-
tion established platinum deposition in biological tissues. Thus,
further analyses were devoted to the investigation of platinum
distribution in biological tissues.Platinum tissue distribution after BP-C1 course treatment
(multiple injections)
Organs of primary platinum accumulation were kidneys, liver,
spleen and muscular tissue near the injection site (Table 2). Low
platinum concentration in the brain indicated slight transport of
BP-C1 through the blood-brain-barrier, which is in concordance
with the data established for other platinum-containing agents,
for example cisplatin, carboplatin and oxaliplatin[28,48] as well as
for platinum metal complexes in general.[49] Although animal
sample was small (three animals per dosage form), some tenden-
cies for platinum elimination from the organs could be demon-
strated. Muscular tissue near the injection site may be responsible
for the ‘slow’ excretion stage. Even 20 days after the last injection,
this tissue indicated high platinum concentration as well as the
smallest higher-to-lower dose ratio that could be explained by plat-
inum accumulation during the first experimental series, when
sacrificed animals of the 0.05% dosage subgroup received higher
dose of 0.125%. Notably, intact muscles (taken from forelegs with
no BP-C1 injections) also showed somewhat elevated platinum
accumulation along with pancreas and skin.. Drug Testing and
y John Wiley & Sons Ltd.
wileyonlinelibrary.com/journal/dta
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42Tissue distribution of platinum-containing agents was not stud-
ied thoroughly enough, especially in case of the course treatment.
For Saliplatin, SM-54111 [cis-3,5-diisopropylsalylic cyclohexano-
diaminoplatinum (II)] primary accumulation was demonstrated to
take place in spleen, liver, and kidneys (0.5–3 h of observation),[50]
but data for course treatment are absent. Shimakura et al.[51]
studied platinum tissue distribution in canine tissues after single
intra-arterial administration of SM-11355 [cis[((1R,2R)-1,
2-cyclohexanediamine-N,N’)bis(myristato)]platinum (II)] simulta-
neously with lipiodol; main accumulation sites were liver and gall
bladder. Egger et al.[10] investigated spatial platinum distribution
in murine kidney and spleen after single intraperitoneal injection
of cisplatin; main platinum accumulation was detected in kidneys
and, secondly, in liver. For orally administered [(OC-6-43)-bis
(acetato) (1-adamantylamine) amminedichloroplatinum (IV)] main
accumulation organs in rats 24 and 48 h after injection were also
liver, kidneys and spleen.[52] Similar results were obtained for
[cis-diammine-1,1-(3-cyclobutanone) dicarboxylate platinum (II)]
after intravenous injection in rats.[53] Esteban-Fernandez et al.[54]
studied distribution of platinum, originating from cisplatin,
carboplatin, and oxaliplatin, in cellular compartments of side effect
affected organs – inner ear, brain, kidney and liver; primary accumu-
lationwas found for kidney and liver for all compounds, whereas for
carboplatinwas found to bemuch less distributed into brain and in-
ner ear. Wang et al.[55] reported blood plasma pharmacokinetics
and tissue distribution of cisplatin, carboplatin and 5 experimental
anti-cancer agents; main deposition was found for kidney for inves-
tigated agents. Noteworthy, in most distribution studies, which
concern platinum-containing drugs, mainly intravenous (for
human-based designs) or also intra-peritoneal (for non-clinical
studies) routes of administration are employed.[54,56–59] That is
why media such as skin and muscle tissue are not investigated as
usual. However, in case of BP-C1, we observed some platinum
retention even for intact skin and muscles, so this is also possible
for other agents. That was previously observed only for carboplatin
injected intravenously to rats.[60] Considerable platinum content
was observed for skin and muscle comparable to spleen, intestine,
blood and even liver but still much lover than that of kidney.[60] In-
terestingly, for our results kidney also showed quite high platinum
retention, however, if compared to other studies,[54,55,60] lower ratio
of kidney to other platinum accumulating tissues (liver, spleen and
muscle) was observed. Thus, lower nephrotoxicity may be assumed
for BP-C1 than that of existing platinum-containing anticancer
drugs. Finally, preliminary protein binding studies for BP-C1
conducted in our group (unpublished results) showed higher
proportion of protein-unbound platinum compared to existing
platinum-containing agents, first of all cisplatin, and their slower
elimination from the system bloodstream. Anyway, truly prolonged
elimination from the organism is very typical for platinum. For
instance, for mature teratoma platinum is detected in the tissue
more than 7 years after cisplatin administration.[22]Conclusion
Amethod of platinum quantification in whole blood and biological
tissues after microwave digestion using sector field mass spectrom-
etry was developed. Main analytical figures of merit – detection
limit, dynamic range, accuracy, and repeatability – were estimated.
Pharmacokinetics of the novel antitumor agent BP-C1 (dosage
forms 0.125% and 0.05%) was studied in rabbits after intramuscular
injection using the developed method. Two dosage forms of BP-C1wileyonlinelibrary.com/journal/dta © 2015 The Authors. D
Analysis published bywere shown to be dose proportional. The possibility of BP-C1 ad-
ministration for 5 days followed by 2 days breaks was shown. Sta-
tionary concentration was observed after ca. 2 weeks of course
treatment. Platinum tissue distribution in rabbit tissue was studied
20 days after the end of the course treatment. Primary metal accu-
mulation was shown in kidneys, liver andmuscles near the injection
site. Observed ‘slow’ platinum elimination may also be related to
the injection site muscles. Next stage of BP-C1 pharmacokinetics
testing should be devoted to examination of ultrafilterable plati-
num originating from the agent.
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